Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial
Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Joseph Tintelnot(Universität Hamburg), Bert Hildebrandt(Charité - Universitätsmedizin Berlin), Benjamin Garlipp(University Hospital Magdeburg), Jörg Steighardt, Thomas Göhler, Fabian Maximilian Meinert(Charité - Universitätsmedizin Berlin), Stefan Ibach, Heinz‐Gert Hoeffkes(Klinikum Fulda), Thomas Edelmann(Praxis für Hämatologie und Onkologie), K Borchert(University Hospital Magdeburg), Ulrich Kaiser(University of Applied Sciences Landshut), Carsten Bokemeyer(Universität Hamburg), Arndt Vogel(Princess Margaret Cancer Centre), Helmut Forstbauer, Stephan Kanzler(Leopoldina Krankenhaus Schweinfurt), Alexander Stein(Universität Hamburg), Carla Hannig(Praxis für Hämatologie und Onkologie), Jörn Rüssel(Martin Luther University Halle-Wittenberg), Julia Mann(Universität Hamburg), Franziska Cygon(University Hospital in Halle), C Roll(Klinikum Magdeburg), Eray Goekkurt(Sorbonne Université)
Cited by 11
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
|Annals of Internal Medicine|2020|2.4k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k